Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 3-13 (IGHV3-13) is a gene segment that encodes the variable region of the heavy chain of immunoglobulins (antibodies), specifically within subgroup 3 of human immunoglobulin heavy variable genes[1][3][8]. IGHV3-13 contributes to the diversity of antigen recognition by forming part of the antigen-binding site in antibodies, participating in the V-(D)-J rearrangement and somatic hypermutation processes in B lymphocytes, which are crucial for the functioning and adaptability of the humoral immune response[1]. IGHV3-13 itself is not a therapeutic receptor, enzyme, or direct drug target, but rather a genomic element enabling antibody diversity[1][2][4]. It does not interact directly with drugs nor is it typically used as a biomarker or safety concern; rather, it is one of many segments generating the immense variability required for effective immune surveillance[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy variable 3-13 (IGHV3-13).